Is change good for you? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Is change good for you?


Pharmaceutical Technology Europe
Volume 22, Issue 2


Fedra Pavlou
With the pharmaceutical industry being in a current state of unrest in light of the recent spate of mergers, acquisitions, job cuts, divestments, patent expiries, and so on, we wanted to know how you felt about all these changes that will have directly or indirectly affected you. So towards the end of last year, we invited visitors to our website to participate in our weekly poll, which revealed some interesting results ( http://www.pharmtech.com/polls).

When we asked our readers what their feelings were towards the M&As of 2009, an astonishing 56% of you felt that the deals will have an overall negative effect on the dynamics of the 2010 pharma industry. This makes for worrying reading given that a number of market analysts have predicted further M&A activity this year. In fact, more than half of you do not believe that the industry will begin to recover from the aftermath of recession until at least 2011. Please go to "Your predictions for 2010" of this issue to read more about our findings.

Our survey results have indeed been enlightening and have indicated your sense of unease given the changes that have been taking place in the industry. Moving forward, we will continue to seek your opinions on industry trends and issues and we will highlight some of the results in our issues throughout the year. I would like to encourage you to take part in these short, one-question polls; however, if you would like to discuss anything further on any of our surveys, we would be delighted to welcome you into our LinkedIn group ( http://www.pharmtech.com/linkedin). As always, your comments and opinions are important to us so please do join your peers and get involved in our regular polls and forums.

On another note, you may have noticed this month's launch of the latest product to our portfolio: PTE Digital. Created to provide you with a snapshot of a different sector of the pharmaceutical industry each month — covering issues, innovations, techniques and products — it is our aim to provide you with a downloadable, comprehensive digital archive of special industry features. If you do not already receive it, please go to http://www.pharmtech.com/signup and select the option to sign up to Pharmaceutical Technology Europe Digital Edition.

Thank you and kindest regards,




Fedra Pavlou

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here